Adjuvant Capital

About The Fund

Adjuvant Capital is a venture capital firm with a mission to deploy capital into the most promising life science technologies aimed at addressing high-burden public health challenges. Operating with an investment sweet spot of $1,500,000 and a fund range of $100,000 to $5,000,000, the firm supports projects through Seed, Series A, and Series B funding stages, with a focus on building a healthier future for all, especially in underserved markets. Their portfolio targets innovations for infectious diseases such as HIV/AIDS, tuberculosis, malaria, tropical diseases including schistosomiasis and onchocerciasis, as well as pandemic threats like Middle East Respiratory Syndrome (MERS), Lassa fever, and tackling antimicrobial resistance (AMR). Adjuvant Capital prioritizes maternal and child health, nutrition, and reproductive and sexual health technologies. They are driven by larger global trends such as climate change, women's empowerment, urbanization, and globalization which help guide their investments towards innovations designed for impactful medical advancements. Their unique expertise and vision are centered on leveraging life science investment to generate both social and financial returns, by fostering novel technologies designed to improve global health, and ensuring accessibility for those in greatest need. With assets under management worth $300,000,000, they stand dedicated to fostering growth in life sciences sectors traditionally overlooked by investment capital, thereby generating differentiated "double-bottom-line" returns for investors. Adjuvant Capital distinguishes itself from traditional venture capital firms through its commitment to improving global health, investing in an evolving world, and backing innovations that promise transformative impacts on public health in emerging economies and low-income populations.